IndustryCompany release

Climb Bio's budoprutug shows early immune responses in Phase 2 membranous nephropathy study

🇺🇸 Climb Bio, Inc. (CLYM) · Mon 26 Oct 2026

Initial PrisMN data presented at ASN Kidney Week show PLA2R antibody reductions and early remissions with the anti-CD19 antibody, with no treatment-related serious adverse events reported.

Climb Bio presented initial Phase 2 PrisMN data for budoprutug, its anti-CD19 antibody, in primary membranous nephropathy at ASN Kidney Week in Denver on 24 October 2026.

In the 200 mg cohort, patients showed a mean 70% reduction in PLA2R antibodies at 12 weeks. Five of 13 patients in that cohort reached immunologic remission by that point.

Early data from the 600 mg cohort pointed to deeper B-cell depletion than seen at the lower dose. The company reported no treatment-related serious adverse events. The available information does not give further detail on the size of the higher-dose cohort or on follow-up duration.

Budoprutug holds US FDA Orphan Drug and Fast Track designations for this indication. Climb Bio expects to report further data in 2027.

What it means for your team

  • The data are early and come from a Phase 2 study; the 12-week readout is a biomarker-based measure, so regulatory relevance will depend on longer follow-up.
  • Existing FDA Orphan Drug and Fast Track designations may support more frequent regulatory interaction, though no filing plans were stated in the available information.
  • Pharmacovigilance teams should watch for fuller safety data in 2027, particularly at the higher 600 mg dose, where only early results have been shared.

Company's press release (SEC filing): Climb Bio, Inc. ↗

Article written by VigiEye from the official source (Climb Bio, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →